Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial

Pablo Ryan, José L Blanco, Mar Masiá, Lucio García‐Fraile, María José Crusells, Peré Domingo, Adrián Curran, Robert Güerri‐Fernández, Enrique Bernal, Joaquín Bravo Urbieta,

The Lancet HIV · 2025 · 19 citations · 23 references

Concepts

References

23